Alkem Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 18.9%)
- Efficient capital deployment (ROCE 21.2%)
- Attractively valued vs sector (P/E 27.3x vs industry 54.7x)
- Low debt relative to equity (D/E 0.1x)
- Near 52-week low — potential value zone (₹5,075)
Concerns
Today's Price Action
Alkem Laboratories Limited (ALKEM) is trading at ₹5,190, unchanged from the previous session. The‑day volume of 63,261 shares exactly matches the 20‑day average, indicating that current participation is typical for the stock and that there is no immediate surge or drop in trader interest.
Valuation Snapshot
The trailing P/E ratio stands at 28.2, which is higher than the implicit sector benchmark of zero, reflecting a premium valuation relative to peers that currently lack a meaningful earnings multiple. A return on equity of 18.9 % demonstrates solid profitability and efficient capital deployment.
Key Levels to Watch
The current price sits just above the lower‑bound of the 52‑week range (₹5,075) and remains comfortably below the upper‑bound (₹5,934), suggesting limited upside pressure from the historic ceiling. Open‑interest data on the nearest expiry shows a modest concentration around ₹5,150‑₹5,200, providing a tentative support‑resistance band based on options positioning.
Chart Pattern
On the daily chart, a bearish engulfing candle appeared five trading days ago, engulfing the prior green candle. This pattern signals a potential shift in short‑term momentum, as the larger red body entirely covers the previous session’s price range.
Data Summary
Key metrics for ALKEM include a market‑capitalisation listed as ₹0 Cr, a P/B ratio of zero, and a stable trading range between ₹5,075 and ₹5,934 over the past year. The stock’s volume aligns with its 20‑day average, and the recent bearish engulfing formation adds to the technical narrative without implying a directional bias.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ALKEM · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 56.74% | 56.74% | 56.38% | 55.66% | 55.66% | 55.13% |
| FII | 8.49% | 9.11% | 8.69% | 9.02% | 10.14% | 9.40% |
| DII | 15.91% | 15.63% | 18.56% | 19.21% | 18.01% | 19.42% |
| Public | 18.86% | 18.51% | 16.37% | 16.12% | 16.19% | 16.05% |
Corporate Events
Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company )
Dividend - Rs 10 Per Share
Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026, inter alia:(i) To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended
Interim Dividend - Rs 43 Per Share
Dividend - Rs 8 Per Share
Interim Dividend - Rs 37 Per Share
Dividend - Rs 5 Per Share
Record: 9 Aug 2024
Interim Dividend - Rs 35 Per Share
Record: 16 Feb 2024
Dividend - Rs 10 Per Share
Latest News
All newsAlkem Laboratories announces board meeting outcome
*Alkem Laboratories announces outcome of board meeting.* No major financial or strategic decisions disclosed. Event pertains to routine corporate governance. Details remain limited to standard disclosures. 📊 *STOCKS:* $ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Alkem Laboratories files general updates with NSE
*Alkem Laboratories files general updates with NSE* as required under SEBI LODR Regulations. The filing is a routine disclosure compliance with no specific financial or operational details provided. Such updates are standard and do not indicate immediate business changes. 📊 *STOCKS:* $ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #RegulatoryFiling
Alk combusts investor presentation without major updates
*Alkem Laboratories released an investor presentation with no major announcements.* The document outlines business strategy and portfolio updates but lacks new financial figures or guidance. No significant changes in operations or management were disclosed. 📊 *STOCKS:* $ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation
Alkem Laboratories shares may react to newspaper publication
*Alkem Laboratories shares may react to newspaper publication.* The company filed a copy of a newspaper publication with the exchange, indicating a regulatory disclosure. Such filings are typically routine and part of compliance norms. No financial impact is immediately evident. 📊 *STOCKS:* ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation
Alkem Labs hosts investor meet for updates
*Alkem Labs hosts investor meet for updates.* The company conducted an analyst and institutional investor meet to share business updates and strategic outlook. No major announcements were disclosed. The event aims to enhance transparency ahead of upcoming earnings. 📊 *STOCKS:* ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Alkem Labs to host analyst and investor meet
*Alkem Labs to host analyst and investor meet.* The company will provide updates during the conference call. **No financial figures or major announcements** were disclosed in the filing. Event scheduled as part of regular investor outreach. 📊 *STOCKS:* ALKEM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Alkem Laboratories updates on acquisition under SEBI LODR regulations
*Alkem Laboratories updates on acquisition under SEBI LODR regulations.* The company has filed disclosures as per Regulation 30 of SEBI LODR, informing about an acquisition-related development. Details of the transaction size or target are not specified in the headline. The update is compliance-driven and lacks immediate financial metrics. 📊 *STOCKS:* ALKEM | 🏢 *SECTOR:* Regulation | #LOWIMPACT #SEBI
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.7K Cr 6.6% | ₹4.0K Cr 18.7% | ₹3.4K Cr 7.2% | ₹3.1K Cr 6.8% | ₹3.4K Cr 1.2% | ₹3.4K Cr 12.6% | ₹3.0K Cr 3.3% | ₹2.9K Cr |
| Op. Profit | ₹828 Cr 10.1% | ₹921 Cr 24.6% | ₹739 Cr 89.0% | ₹391 Cr 48.5% | ₹759 Cr 0.8% | ₹753 Cr 23.6% | ₹609 Cr 51.5% | ₹402 Cr |
| OPM | 22.0% 4.3% | 23.0% 4.5% | 22.0% 83.3% | 12.0% 47.8% | 23.0% 4.5% | 22.0% 10.0% | 20.0% 42.9% | 14.0% |
| Net Profit | ₹653 Cr 16.2% | ₹779 Cr 16.6% | ₹668 Cr 107.5% | ₹322 Cr 49.8% | ₹641 Cr 8.7% | ₹702 Cr 27.6% | ₹550 Cr 80.9% | ₹304 Cr |
| EPS (₹) | 53.19 16.9% | 63.99 15.2% | 55.56 117.2% | 25.58 51.1% | 52.34 9.1% | 57.6 26.3% | 45.6 85.7% | 24.55 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.7K Cr 13.5% | ₹13.0K Cr 2.3% | ₹12.7K Cr 9.2% | ₹11.6K Cr 9.1% | ₹10.6K Cr 20.0% | ₹8.9K Cr 6.2% | ₹8.3K Cr 13.4% | ₹7.4K Cr 14.9% | ₹6.4K Cr 12.5% | ₹5.7K Cr |
| Expenses | ₹11.7K Cr 12.0% | ₹10.5K Cr 0.3% | ₹10.4K Cr 4.4% | ₹10.0K Cr 16.3% | ₹8.6K Cr 24.0% | ₹6.9K Cr 0.8% | ₹6.9K Cr 10.1% | ₹6.2K Cr 15.7% | ₹5.4K Cr 15.0% | ₹4.7K Cr |
| Op. Profit | ₹3.0K Cr 19.7% | ₹2.5K Cr 11.7% | ₹2.2K Cr 38.7% | ₹1.6K Cr 21.0% | ₹2.1K Cr 5.6% | ₹1.9K Cr 31.8% | ₹1.5K Cr 31.8% | ₹1.1K Cr 11.0% | ₹1.0K Cr 0.8% | ₹1.0K Cr |
| OPM | 20.0% 5.3% | 19.0% 5.6% | 18.0% 28.6% | 14.0% 26.3% | 19.0% 13.6% | 22.0% 22.2% | 18.0% 20.0% | 15.0% 6.3% | 16.0% 11.1% | 18.0% |
| Other Income | ₹407 Cr 17.6% | ₹494 Cr 165.6% | ₹186 Cr 84.2% | ₹101 Cr 30.8% | ₹146 Cr 36.5% | ₹230 Cr 125.5% | ₹102 Cr 24.4% | ₹82 Cr 28.7% | ₹115 Cr 4.5% | ₹110 Cr |
| Interest | ₹161 Cr 32.0% | ₹122 Cr 8.9% | ₹112 Cr 4.7% | ₹107 Cr 105.8% | ₹52 Cr 11.9% | ₹59 Cr 9.2% | ₹65 Cr 18.2% | ₹55 Cr 0.0% | ₹55 Cr 22.2% | ₹45 Cr |
| Depreciation | ₹382 Cr 7.0% | ₹357 Cr 19.4% | ₹299 Cr 3.5% | ₹310 Cr 2.0% | ₹304 Cr 10.5% | ₹275 Cr 8.7% | ₹253 Cr 31.1% | ₹193 Cr 35.0% | ₹143 Cr 41.6% | ₹101 Cr |
| PBT | ₹2.9K Cr 13.6% | ₹2.5K Cr 24.9% | ₹2.0K Cr 55.0% | ₹1.3K Cr 29.2% | ₹1.8K Cr 0.1% | ₹1.8K Cr 46.2% | ₹1.3K Cr 31.9% | ₹955 Cr 3.1% | ₹926 Cr 4.0% | ₹965 Cr |
| Tax % | 18.0% 50.0% | 12.0% 20.0% | 10.0% 56.5% | 23.0% 155.6% | 9.0% 25.0% | 12.0% 33.3% | 9.0% 52.6% | 19.0% 38.7% | 31.0% 416.7% | 6.0% |
| Net Profit | ₹2.4K Cr 6.1% | ₹2.2K Cr 22.3% | ₹1.8K Cr 79.8% | ₹1.0K Cr 40.1% | ₹1.7K Cr 3.8% | ₹1.6K Cr 40.8% | ₹1.1K Cr 48.4% | ₹774 Cr 21.3% | ₹638 Cr 29.5% | ₹905 Cr |
| EPS (₹) | 192.51 6.3% | 181.11 20.6% | 150.19 82.5% | 82.31 40.2% | 137.63 3.8% | 132.57 40.6% | 94.26 48.2% | 63.61 20.5% | 52.77 29.3% | 74.61 |
| Div Payout | 28.0% 12.0% | 25.0% 7.4% | 27.0% 55.7% | 61.0% 144.0% | 25.0% 8.7% | 23.0% 14.8% | 27.0% 8.0% | 25.0% 0.0% | 25.0% 25.0% | 20.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr 0.0% | ₹24 Cr |
| Reserves | ₹13.3K Cr 11.4% | ₹12.0K Cr 16.3% | ₹10.3K Cr 14.0% | ₹9.0K Cr 4.7% | ₹8.6K Cr 17.1% | ₹7.4K Cr 19.8% | ₹6.1K Cr 13.3% | ₹5.4K Cr 11.9% | ₹4.8K Cr 8.9% | ₹4.4K Cr |
| Borrowings | ₹2.4K Cr 70.6% | ₹1.4K Cr 2.6% | ₹1.4K Cr 1.5% | ₹1.4K Cr 47.6% | ₹2.7K Cr 56.3% | ₹1.7K Cr 5.6% | ₹1.6K Cr 71.2% | ₹944 Cr 5.4% | ₹998 Cr 51.4% | ₹659 Cr |
| Other Liabilities | ₹4.6K Cr 6.0% | ₹4.3K Cr 12.5% | ₹3.8K Cr 16.0% | ₹3.3K Cr 20.0% | ₹2.8K Cr 13.5% | ₹2.4K Cr 12.3% | ₹2.2K Cr 18.9% | ₹1.8K Cr 1.2% | ₹1.8K Cr 25.2% | ₹1.4K Cr |
| Total Liabilities | ₹20.3K Cr 14.7% | ₹17.7K Cr 13.6% | ₹15.6K Cr 13.2% | ₹13.8K Cr 2.2% | ₹14.1K Cr 22.1% | ₹11.5K Cr 15.8% | ₹9.9K Cr 21.2% | ₹8.2K Cr 7.1% | ₹7.7K Cr 16.7% | ₹6.6K Cr |
Assets | ||||||||||
| Fixed Assets | ₹3.3K Cr 16.4% | ₹2.9K Cr 0.7% | ₹2.9K Cr 7.1% | ₹2.7K Cr 7.5% | ₹2.9K Cr 3.9% | ₹2.8K Cr 4.0% | ₹2.9K Cr 14.9% | ₹2.5K Cr 10.8% | ₹2.3K Cr 27.1% | ₹1.8K Cr |
| CWIP | ₹653 Cr 19.2% | ₹548 Cr 244.7% | ₹159 Cr 50.8% | ₹323 Cr 4.7% | ₹339 Cr 13.7% | ₹393 Cr 8.3% | ₹363 Cr 26.4% | ₹493 Cr 29.4% | ₹381 Cr 27.4% | ₹299 Cr |
| Investments | ₹2.5K Cr 37.2% | ₹1.8K Cr 281.4% | ₹484 Cr 22.2% | ₹622 Cr 67.7% | ₹371 Cr 11.4% | ₹333 Cr 27.6% | ₹261 Cr 19.4% | ₹324 Cr 27.0% | ₹444 Cr 19.7% | ₹553 Cr |
| Other Assets | ₹13.8K Cr 10.8% | ₹12.4K Cr 3.2% | ₹12.1K Cr 19.1% | ₹10.1K Cr 3.1% | ₹10.5K Cr 30.7% | ₹8.0K Cr 24.7% | ₹6.4K Cr 31.9% | ₹4.9K Cr 6.7% | ₹4.6K Cr 16.3% | ₹3.9K Cr |
| Total Assets | ₹20.3K Cr 14.7% | ₹17.7K Cr 13.6% | ₹15.6K Cr 13.2% | ₹13.8K Cr 2.2% | ₹14.1K Cr 22.1% | ₹11.5K Cr 15.8% | ₹9.9K Cr 21.2% | ₹8.2K Cr 7.1% | ₹7.7K Cr 16.7% | ₹6.6K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.9K Cr 1.8% | ₹1.9K Cr 15.8% | ₹1.7K Cr 51.4% | ₹1.1K Cr 12.2% | ₹1.3K Cr 116.2% | ₹585 Cr 25.0% | ₹780 Cr 193.2% | ₹266 Cr 43.5% | ₹471 Cr 35.1% | ₹726 Cr |
| Investing CF | ₹-1.3K Cr 27.4% | ₹-1.0K Cr 942.5% | ₹120 Cr 108.4% | ₹-1.4K Cr 44.0% | ₹-995 Cr 35.0% | ₹-737 Cr 131.8% | ₹-318 Cr 9.4% | ₹-351 Cr 19.4% | ₹-294 Cr 243.4% | ₹205 Cr |
| Financing CF | ₹-811 Cr 29.2% | ₹-1.1K Cr 35.0% | ₹-1.8K Cr 563.4% | ₹380 Cr 239.7% | ₹-272 Cr 444.3% | ₹79 Cr 120.8% | ₹-379 Cr 545.9% | ₹85 Cr 161.6% | ₹-138 Cr 85.1% | ₹-927 Cr |
| Net Cash Flow | ₹-186 Cr 10.1% | ₹-207 Cr 592.9% | ₹42 Cr 27.6% | ₹58 Cr 3000.0% | ₹-2 Cr 97.3% | ₹-73 Cr 189.0% | ₹82 Cr | ₹0 Cr 100.0% | ₹40 Cr 1233.3% | ₹3 Cr |
| Free Cash Flow | ₹1.3K Cr 27.4% | ₹1.8K Cr 21.2% | ₹1.5K Cr 85.6% | ₹783 Cr 29.8% | ₹1.1K Cr 370.9% | ₹237 Cr 6.3% | ₹253 Cr 161.6% | ₹-411 Cr 152.1% | ₹-163 Cr 134.5% | ₹472 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 69d 6.2% | 65d 3.0% | 67d 3.1% | 65d 1.5% | 66d 8.3% | 72d 16.1% | 62d 0.0% | 62d 34.8% | 46d 9.5% | 42d |
| Inventory Days | 224d 13.7% | 197d 1.5% | 194d 26.0% | 262d 8.7% | 241d 21.7% | 198d 6.5% | 186d 15.8% | 221d 11.6% | 198d 17.2% | 169d |
| Days Payable | 148d 14.7% | 129d 48.3% | 87d 14.7% | 102d 8.9% | 112d 7.7% | 104d 12.6% | 119d 19.0% | 147d 20.5% | 122d 13.0% | 108d |
| Cash Conv. Cycle | 145d 9.8% | 132d 24.1% | 174d 22.7% | 225d 14.8% | 196d 17.4% | 167d 29.5% | 129d 4.4% | 135d 10.7% | 122d 18.4% | 103d |
| Working Capital Days | 123d 8.9% | 135d 104.5% | 66d 112.9% | 31d 35.4% | 48d 9.1% | 44d 20.0% | 55d 37.5% | 40d 17.6% | 34d 161.5% | 13d |
| ROCE | 20.0% 0.0% | 20.0% 42.9% | 14.0% 22.2% | 18.0% 18.2% | 22.0% 22.2% | 18.0% 12.5% | 16.0% 5.9% | 17.0% 19.0% | 21.0% 8.7% | 23.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
HealthcarePharmaceuticals & Biotechnology